Scarica l'app Stockscreener
48.73
2.42%
-1.21
Dopo l'orario di chiusura:
49.00
0.27
+0.55%
Veracyte Inc Borsa (VCYT) Ultime notizie
FMR LLC holds 8.06M Veracyte (VCYT) shares, representing 10.1% - Stock Titan
Veracyte Insider Sold Shares Worth $6,919,585, According to a Recent SEC Filing - marketscreener.com
Veracyte CFO Rebecca Chambers sells $177,082 in company stock By Investing.com - Investing.com Canada
Veracyte global chief commercial off sells $699,732 in stock By Investing.com - Investing.com Canada
Veracyte EVP Annie McGuire sells $158k in company stock By Investing.com - Investing.com Canada
Veracyte CEO Marc Stapley sells $6.9m in company shares By Investing.com - Investing.com Canada
Veracyte CFO Rebecca Chambers sells $177,082 in company stock - Investing.com
Veracyte (VCYT) CFO trades shares as RSUs vest and 10b5-1 plan executes - Stock Titan
Veracyte (VCYT) CCO sells 13,975 shares under 10b5-1 plan, keeps 132K - Stock Titan
Veracyte global chief commercial off sells $699,732 in stock - Investing.com
Veracyte CEO Marc Stapley sells $6.9m in company shares - Investing.com
[144] VERACYTE, INC. SEC Filing - stocktitan.net
VCYT (NASDAQ) insider 10b5-1 sale of 10,204 shares; 3,176 RSUs registered - Stock Titan
VCYT Stock Price, Quote & Chart | VERACYTE INC (NASDAQ:VCYT) - ChartMill
How Veracyte (VCYT) Investors Can Read The Latest Unchanged Analyst Call - Yahoo Finance
Why Is Veracyte (VCYT) Up 18.2% Since Last Earnings Report? - Yahoo Finance
Veracyte, Inc. (VCYT) Discusses ASCO Findings From OPTIMA and ENZAMET Phase III Trials in Breast and Prostate CancerSlideshow (NASDAQ:VCYT) 2026-06-03 - Seeking Alpha
Veracyte, Inc. (VCYT) Presents at 46th Annual William Blair Growth Stock ConferenceSlideshow - Seeking Alpha
Veracyte stock price target maintained at $42 by Canaccord on study results - Investing.com
Veracyte (VCYT) Launches Prosigna Breast Cancer Risk Test in the U.S. - GuruFocus
Wolfe Research initiates Veracyte stock coverage with Outperform rating By Investing.com - Investing.com South Africa
Wolfe Research initiates Veracyte stock coverage with Outperform rating - Investing.com
VCYT Maintained by Needham -- Price Target Raised to $57.00 - GuruFocus
Needham raises Veracyte stock price target to $57 on trial data By Investing.com - Investing.com South Africa
Needham raises Veracyte stock price target to $57 on trial data - Investing.com Australia
Veracyte (VCYT) Launches Prosigna Breast Risk Test for Cancer Pr - GuruFocus
Needham Maintains Veracyte(VCYT.US) With Buy Rating, Raises Target Price to $57 - Moomoo
Veracyte launches Prosigna breast cancer test in U.S. By Investing.com - Investing.com Australia
Veracyte Inc Investor Call on ASCO Findings Transcript - GuruFocus
Veracyte launches Prosigna breast cancer test in U.S. - Investing.com
Veracyte Announces Commercial Launch of the Prosigna Breast Test in the U.S. - standard-journal.com
Veracyte Inc stock (US92347M1009): Nasdaq diagnostics name steadies after recent gains - AD HOC NEWS
ENZAMET Trial Shows Veracyte's Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate Cancer - BioSpace
Breast and prostate cancer test data: Veracyte schedules June 1 call - Stock Titan
Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte’s Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy - BioSpace
Veracyte (VCYT) Unveils Promising Findings from Enzamet Trial - GuruFocus
Veracyte Says Enzamet Trial Shows Decipher Prostate Test Identifies Chemotherapy Benefit In Metastatic Prostate Cancer - TradingView
Study shows which prostate cancer patients can safely skip chemotherapy - Stock Titan
Here's how much you'd have if you invested $1000 in Veracyte a decade ago - MSN
Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Ve - The National Law Review
A Look at Veracyte Inc (VCYT) After 7.8% Gain -- GF Value $37.84 vs Price $47.99 - GuruFocus
Needham Maintains Veracyte(VCYT.US) With Buy Rating, Maintains Target Price $48 - Moomoo
Veracyte: The Evidence Flywheel Is Turning Into A Cash Flow Platform (NASDAQ:VCYT) - Seeking Alpha
Veracyte chief accounting officer sells $1.09m in stock By Investing.com - Investing.com Nigeria
Veracyte chief accounting officer sells $1.09m in stock - Investing.com
Veracyte (VCYT) CAO exercises options and sells 24,000 shares in Form 4 filing - Stock Titan
Is it Worth Retaining Veracyte Stock in Your Portfolio for Now? - TradingView
Veracyte genomic test identifies breast cancer patients who can skip chemo - whbl.com
How Veracyte Inc. (VCYT) Affects Rotational Strategy Timing - Stock Traders Daily
Here's why Veracyte (VCYT) is a strong momentum stock - MSN
2.13%
2.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):